Polyenthesitis during treatment with dupilumab for atopic dermatitis

Dupilumab is a monoclonal antibody against interleukin-4 (IL-4) receptor that inhibits IL-4 and IL-13 signaling, which plays a central role in type 2 inflammation in atopic dermatitis (AD) (1). Although dupilumab exerts significant therapeutic effects for AD, it occasionally causes some unexpected side effects including conjunctivitis (2), psoriasis (3), and polyenthesitis (4, 5). Here we report the first Asian case of polyenthesitis during the treatment with dupilumab.